Malignant mesothelioma of the pericardium: Case reports and immunohistochemical studies including Ki-67 expression

Pathology International

Volumn 52, Issue 10, 2002, Pages 669-676

  Hirano, Hiroshi ^a   Maeda, Tamaki ^b   Tsuji, Motomu ^c   Ito, Yasuhiro ^d   Kizaki, Tomohiko ^e   Yoshii, Yasuyosi ^c   Sashikata, Terumasa ^e  

^a TONEYAMA NATIONAL HOSPITAL   (Japan)

^b KOBE TOKIWA UNIVERSITY   (Japan)

^c OSAKA MEDICAL COLLEGE   (Japan)

^d Mino City Hospital   (Japan)

^e HYOGO MEDICAL CENTER FOR ADULTS   (Japan)

Author keywords

Immunohistochemistry; Ki 67; Malignant mesothelioma; Pericardium

Indexed keywords

KI 67 ANTIGEN;

ADULT; ANTIGEN EXPRESSION; ARTICLE; AUTOPSY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER INVASION; CASE REPORT; CLINICAL FEATURE; CONTROLLED STUDY; HEART CARCINOMA; HEART FAILURE; HEART FUNCTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABELING INDEX; MALE; MESOTHELIOMA; MORTALITY; PERICARDIUM; PLEURA CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PUBLISHING; THICKNESS; TIME;

EID: 0036433238     PISSN: 13205463     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1827.2002.01404.x     Document Type: Article

References (34)

1. Hillerdal G. Malignant mesothelioma 1982. Review of 4710 published cases. Br. J. Dis. Chest 1983;77: 321-343.
2. Dawe CJ, Wood DA, Mitchell S. Diffuse fibrous mesothelioma of the pericardium: Report of a case and review of the literature. Cancer 1953;6: 794-808.
3. Sytman AL, MacAlpin RM. Primary pericardial mesothelioma: Report of two cases and review of the literature. Am. Heart J. 1971;81: 760-769.
4. Fazekas T, Ungi I, Tiszlavicz L. Primary malignant mesothelioma of the pericardium. Am. Heart J. 1992;124: 227-231.
5. Battifora H, McCaughey E.Primary Tumors of the Pericardium and Heart. Atlas of Tumor Pathology, Tumor of the Serosal Membrane. Armed Forces Institute of Pathology, Washington, DC, 1995; 17-23.
6. Dooley BN, Colonel L, Beckmann C, Hood RH. Primary mesothelioma of the pericardium: Successful surgical removal. J. Thorac. Cardio. Surg. 1968;55: 719-724.
7. Patrick M, Chun KC, Leeburg CW, Coggin JT, Zajtchuk CR. Primary pericardial malignant epithelial mesothelioma causing acute myocardial infarction. Chest 1980;77: 559-561.
8. Anderson JA, Hansen BF. Primary pericardial mesothelioma. Danish Med. Bull. 1974;21: 195-200.
9. Becker T. Malignant pericardial mesothelioma. Am. J. Int. Med. 1982;3: 149-159.
10. Travis WD, Colby TV, Corrin B,et al. Histological Type of Lung and Pleural Tumors, World Health Organization, 3rd edn. Springer, Tokyo, 1999; 51-54.
11. Noguchi M, Nakajima T, Hirohashi S, Akiba T, Shinomsato Y. Immunohistochemical distinction of malignant mesothelioma from pulmonary adenocarcinoma with anti-surfactant apo-ptrotein, anti-Lewis, and anti-Tn antibodies.Hum. Pathol. 1989;20: 53-57.
12. Skov BG, Lauritzen AF, Hirsch FR, Skov T, Nielsen HW. Differentiation of adenocarcinoma of the lung and malignant mesothelioma: Predictive value and reproducibility of immunoreactive antibodies. Histopathology 1994;25: 431-437.
13. Collins CL, Ordonez NG, Schaefer R et al. Thrombomodulin expression in malignant pleural mesothelioma and pulmonary adenocarcinoma. Am. J. Pathol. 1992;141: 827-833.
14. Dejmek A, Brockstedt U, Hjerpe A. Optimization of a battery using nine immunocytochemical variables for distinguishing between epithelial mesothelioma and adenocarcinoma. APMIS 1997;105: 889-894.
15. Riera JR, Astengo-Osuna C, Longmate JA, Battifora H. The immunohistochemical diagnostic panel for epithelial mesothelioma: a reevaluation after heat-induced epitope retrieval. Am. J. Surg. Pathol. 1997;21: 1409-1419.
16. Attanoos RL, Goddard H, Gibbs AR. Mesothelioma-binding antibodies: Thrombomodulin, OV 632 and HBME-1 and their use in the diagnosis of malignant mesothelioma. Histopathology 1996;29: 209-215.
17. Wick MR, Loy T, Mills SE, Legier JF, Manivel JR. Malignant epithelial pleural mesothelioma versus peripheral pulmonary adenocarcinoma. A histochemical, ultrastructural, and immunohistologic study of 103 cases. Hum. Pathol. 1990;21: 759-766.
18. Sheibani K, Esteban JM, Bailey A, Battifora H, Weiss LM. Immunopathologic and molecular studies as an aid to the diagnosis of malignant mesothelioma. Hum. Pathol. 1992;23: 107-116.
19. Latza U, Niedobitek G, Schwarting R, Nekarda H, Stein H. Ber-Ep4: new monoclonal antibody which distinguishes epithelia from mesothelia. J. Clin. Pathol. 1990;43: 213-219.
20. Corson JM, Pinkus GS. Mesothelioma profile of keratin proteins and carcinoembryonic antigen; an immunoperoxidase study of 20 cases and comparison with pulmonary adenocarcinoma. Am. J Pathol. 1982;108: 80-87.
21. Dejmek A, Hjerpe A. Carcinoembryonal antigen-like reactivity in malignant mesothelioma. Cancer 1994;73: 464-469.
22. Loosli H, Hurlimann J. Immunohistological study of malignant diffuse mesotheliomas of the pleura. Histopathology 1984; 8: 793-803.
23. Thylen A, Levin-Jacobsen AM, Hjerpe A, Martensson G. Immunohistochemical differences between hyaluronan and non-hyaluronan-producing malignant mesothelioma. Eur. Respir. J. 1997;10: 404-408.
24. Bateman AC, AL-Tilib RK, Newman T, Williams JH, Herbert A. Immunohistochemical phenotype of malignant mesothelioma: predictive value of CA125 and HBME-1 expression. Histopathology 1997;30: 49-56.
25. Fetsch PA, Abati A, Hijazi YM. Utility of the antibodies CA 199, HBME-1, and thrombomodulin in the diagnosis of malignant mesothelioma and adenocarcinoma in cytology. Cancer 1998;25: 101-108.
26. Miettinen M, Limon J, Niezabitowski A, Lasota J. Calretinin and other mesothelioma markers in synovial sarcoma: Analysis of antigenic similarities and differences with malignant mesothelioma. Am. J. Surg. Pathol. 2001;25: 610-617.
27. Kennedy AD, King G, Kerr KM. HBME-1 and antithrombomodulin in the differential diagnosis of malignant mesothelioma of pleura. J. Clin. Pathol. 1997;50: 859-862.
28. Churg A. Immunohistochemical staining for vimentin and keratin in malignant mesothelioma. Am. J. Surg. Pathol. 1985; 9: 360-365.
29. Dardick I, Jabi M, MaCaughey WT, Deodhare S, Per AW, Srigley JR. Diffuse epithelial mesothelioma: a review of the ultrastructural spectrum. Ultrastruct. Pathol. 1987; 11: 503-533.
30. Warhol MJ, Corson JM. An ultrastructural comparison of mesotheliomas with adenocarcinomas of the lung and breast. Hum. Pathol. 1985;16: 50-55.
31. Suzuki Y, Churg J, Kannerstein M. Ultrastructure of human malignant diffuse mesothelioma. Am. J. Pathol. 1976;85: 241-262.
32. Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a nuclear antigen associated with cell proliferation. Int. J. Cancer 1983;31: 13-20.
33. Beer TW, Buchanan R. Prognosis in malignant mesothelioma related to Mib-1 proliferation index and histological subtype. Hum. Pathol. 1998;29: 246-255.
34. Kahlos K, Soini Y, Paakko P, Saily M, Linnainmaa K, Kinnnula VL. Proliferation, apoptosis, and manganese superoxide dismutase in malignant mesothelioma. Int. J. Cancer 2000;88: 37-40.